Enliven Therapeutics (ELVN) Stock Forecast & Price Target $44.78 +1.09 (+2.49%) Closing price 10/28/2026 04:00 PM EasternExtended Trading$43.88 -0.90 (-2.00%) As of 10/28/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Enliven Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 12 Analyst RatingsSell2Hold0Buy10 Based on 12 Wall Street analysts who have issued ratings for Enliven Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 2 have given a sell rating, and 10 have given a buy rating for ELVN. Consensus Price Target $75.4468.48% Upside According to the 12 analysts' twelve-month price targets for Enliven Therapeutics, the average price target is $75.44. The highest price target for ELVN is $82.00, while the lowest price target for ELVN is $70.00. The average price target represents a forecasted upside of 68.48% from the current price of $44.78. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ELVN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELVN Analyst Ratings Over TimeTypeCurrent Forecast10/29/25 to 10/29/261 Month Ago9/29/25 to 9/29/263 Months Ago7/31/25 to 7/31/261 Year Ago10/29/24 to 10/29/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy10 Buy rating(s)8 Buy rating(s)5 Buy rating(s)5 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell2 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$75.44$75.00$70.50$41.20Forecasted Upside68.48% Upside61.26% Upside28.63% Upside81.90% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ELVN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ELVN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Enliven Therapeutics Stock vs. The CompetitionTypeEnliven TherapeuticsHealthcare CompaniesBroader MarketConsensus Rating Score 2.67 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside68.48% Upside105.81% Upside16.63% UpsideNews Sentiment RatingPositive NewsSee Recent ELVN NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/29/2024 - 10/29/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/19/2026 HC Wainwright4 of 5 starsRobert Burns5 of 5 starsBoost TargetBuy$65.00 ➝ $73.00+95.61%10/15/2026 Weiss Ratings2 of 5 stars Reiterated RatingSell (D-)10/13/2026 Zacks Research4 of 5 stars DowngradeHold ➝ Strong Sell10/8/2026 GuggenheimSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael SchmitzSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy10/2/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsSean LaamanSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOverweight$70.00+51.48%10/1/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsPriyanka GroverSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOverweight$75.00+63.61%8/18/2026 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankingsAndy HsiehSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform8/18/2026 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsEtzer DaroutSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOverweight$78.00+31.03%8/18/2026 MizuhoSubscribe to MarketBeat All Access to unlock brokerage rankingsSalim SyedSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$62.00 ➝ $73.00+22.63%8/6/2026 Stifel NicolausSubscribe to MarketBeat All Access to unlock brokerage rankingsDara AzarSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$80.00 ➝ $82.00+35.77% Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/6/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsSalveen RichterSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$67.00 ➝ $80.00+34.00%6/29/2026 JonesTradingSubscribe to MarketBeat All Access to unlock brokerage rankingsBoris PeakerSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$45.00 ➝ $70.00+40.07%6/16/2025 Robert W. BairdSubscribe to MarketBeat All Access to unlock brokerage rankingsColleen KusySubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$40.00 ➝ $52.00+137.33%12/13/2024 BTIG ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsJustin ZelinSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy$42.00+82.61%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:26 AM ET. ELVN Forecast - Frequently Asked Questions What is Enliven Therapeutics' forecast for 2026? According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Enliven Therapeutics is $75.44, with a high forecast of $82.00 and a low forecast of $70.00. Should I buy or sell Enliven Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last twelve months. There are currently 2 sell ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ELVN shares. Does Enliven Therapeutics's stock price have much upside? According to analysts, Enliven Therapeutics's stock has a predicted upside of 68.48% based on their 12-month stock forecasts. Has Enliven Therapeutics been downgraded by Wall Street analysts recently? Over the previous 90 days, Enliven Therapeutics's stock had 1 downgrade by analysts. What analysts cover Enliven Therapeutics? Enliven Therapeutics has been rated by research analysts at Barclays, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Weiss Ratings, William Blair, and Zacks Research in the past 90 days. Do Wall Street analysts like Enliven Therapeutics more than its competitors? Analysts like Enliven Therapeutics more than other "healthcare" companies. The consensus rating for Enliven Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ELVN compares to other companies. Stock Forecasts and Research Tools Related Companies BioMarin Pharmaceutical Stock Forecast Madrigal Pharmaceuticals Stock Forecast Krystal Biotech Stock Forecast Vaxcyte Stock Forecast Kymera Therapeutics Stock Forecast ImmunityBio Stock Forecast Protagonist Therapeutics Stock Forecast Spyre Therapeutics Stock Forecast TG Therapeutics Stock Forecast Arrowhead Pharmaceuticals Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Enliven Therapeutics RecommendationsHC WainwrightWeiss RatingsZacks ResearchGuggenheimMorgan StanleyJPMorgan Chase & Co.MizuhoWilliam BlairBarclaysWall Street ZenStifel NicolausThe Goldman Sachs GroupJonesTrading MarketBeat monitors more than a dozen sources for Enliven Therapeutics analyst ratings, with the most recent rating issued on 10/19/2026. From Our PartnersThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
